Renal osteodystrophy, the term used to describe the skeletal complications of end-stage
renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the …

Aluminium is absorbed by the intestines and is rapidly transported into bone, where it
disrupts mineralization and bone cell growth and activity. Its toxicities result in or exacerbate …

Disturbances in mineral and bone metabolism are common in patients with CKD. A large
body of evidence indicates that these derangements are associated with increased mortality …

The spectrum of bone disease in end-stage renal failure—An evolving disorder. We have
assessed the bone histology in 259 chronic dialysis patients, all of whom were in the same …

Results Serum levels of sclerostin and iPTH correlated negatively. In unadjusted analyses,
sclerostin correlated negatively with histomorphometric parameters of turnover, osteoblastic …

Objective: To determine whether alfacalcidol—used in management of overt renal bone
disease—may safely prevent renal bone disease when used earlier in course of renal …

Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet
HCl. Background The National Kidney Foundation's Kidney Disease Outcomes Quality …

Uranium accumulates in bone, affects bone metabolism in laboratory animals, and when
ingested in drinking water increases urinary excretion of calcium and phosphate, important …

Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. To
investigate whether the derangements in calcium kinetics in patients with renal …

Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone
response to PTH. The spectrum of bone disease in predialysis and dialysis patients has …